Cargando…
P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430665/ http://dx.doi.org/10.1097/01.HS9.0000847336.10486.b2 |
| _version_ | 1784779836780183552 |
|---|---|
| author | Wang, M. L. Munoz, J. Goy, A. Locke, F. L. Jacobson, C. A. Hill, B. T. Timmerman, J. M. Holmes, H. Flinn, I. W. Miklos, D. B. Pagel, J. M. Kersten, M. J. Houot, R. Beitinjaneh, A. Peng, W. Fang, X. Shen, R. R. Siddiqi, R. Kloos, I. Reagan, P. M. |
| author_facet | Wang, M. L. Munoz, J. Goy, A. Locke, F. L. Jacobson, C. A. Hill, B. T. Timmerman, J. M. Holmes, H. Flinn, I. W. Miklos, D. B. Pagel, J. M. Kersten, M. J. Houot, R. Beitinjaneh, A. Peng, W. Fang, X. Shen, R. R. Siddiqi, R. Kloos, I. Reagan, P. M. |
| author_sort | Wang, M. L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430665 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94306652022-08-31 P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 Wang, M. L. Munoz, J. Goy, A. Locke, F. L. Jacobson, C. A. Hill, B. T. Timmerman, J. M. Holmes, H. Flinn, I. W. Miklos, D. B. Pagel, J. M. Kersten, M. J. Houot, R. Beitinjaneh, A. Peng, W. Fang, X. Shen, R. R. Siddiqi, R. Kloos, I. Reagan, P. M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430665/ http://dx.doi.org/10.1097/01.HS9.0000847336.10486.b2 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Wang, M. L. Munoz, J. Goy, A. Locke, F. L. Jacobson, C. A. Hill, B. T. Timmerman, J. M. Holmes, H. Flinn, I. W. Miklos, D. B. Pagel, J. M. Kersten, M. J. Houot, R. Beitinjaneh, A. Peng, W. Fang, X. Shen, R. R. Siddiqi, R. Kloos, I. Reagan, P. M. P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 |
| title | P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 |
| title_full | P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 |
| title_fullStr | P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 |
| title_full_unstemmed | P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 |
| title_short | P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2 |
| title_sort | p1117: three-year follow-up of outcomes with kte-x19 in patients with relapsed/refractory mantle cell lymphoma in zuma-2 |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430665/ http://dx.doi.org/10.1097/01.HS9.0000847336.10486.b2 |
| work_keys_str_mv | AT wangml p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT munozj p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT goya p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT lockefl p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT jacobsonca p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT hillbt p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT timmermanjm p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT holmesh p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT flinniw p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT miklosdb p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT pageljm p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT kerstenmj p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT houotr p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT beitinjaneha p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT pengw p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT fangx p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT shenrr p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT siddiqir p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT kloosi p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 AT reaganpm p1117threeyearfollowupofoutcomeswithktex19inpatientswithrelapsedrefractorymantlecelllymphomainzuma2 |